{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:51:34Z","timestamp":1793389894941,"version":"4.5.0"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2024\\u201300413760"],"award-info":[{"award-number":["RS-2024\\u201300413760"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Phytomedicine"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.phymed.2025.156973","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T15:51:42Z","timestamp":1749657102000},"page":"156973","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["4-O-Demethylbarbatic acid has a novel therapeutic impact on the progression of EGFR-driven lung adenocarcinoma"],"prefix":"10.1016","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6175-4015","authenticated-orcid":false,"given":"M\u00fccahit","family":"Varl\u0131","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3785-0159","authenticated-orcid":false,"given":"Rui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rundong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Kyung","family":"Rho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung-Ho","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8547-7075","authenticated-orcid":false,"given":"Jae-Seoun","family":"Hur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5889-8907","authenticated-orcid":false,"given":"Hangun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phymed.2025.156973_bib0001","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2208947119","article-title":"Regulation of EGF-stimulated activation of the PI-3K\/AKT pathway by exocyst-mediated exocytosis","volume":"119","author":"An","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U.S.A"},{"key":"10.1016\/j.phymed.2025.156973_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.103811","article-title":"A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy","volume":"99","author":"Ayati","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.phymed.2025.156973_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13578-017-0197-8","article-title":"Hypoxic 3D in vitro culture models reveal distinct resistance processes to TKIs in renal cancer cells","volume":"7","author":"Bielecka","year":"2017","journal-title":"Cell Biosci."},{"key":"10.1016\/j.phymed.2025.156973_bib0004","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1039\/C7CS00431A","article-title":"Secondary metabolism in the lichen symbiosis","volume":"47","author":"Calcott","year":"2018","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.phymed.2025.156973_bib0005","doi-asserted-by":"crossref","first-page":"4347","DOI":"10.21873\/anticanres.17264","article-title":"Promising approach for optimizing In vivo fluorescence imaging in a tumor mouse model: precision in cancer research","volume":"44","author":"Choi","year":"2024","journal-title":"Anticancer Res."},{"key":"10.1016\/j.phymed.2025.156973_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102664","article-title":"The role of anti-EGFR therapies in EGFR-TKI-resistant advanced non-small cell lung cancer","volume":"122","author":"Ciardiello","year":"2024","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.phymed.2025.156973_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102824","article-title":"Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: bridging biological insights and therapeutic development","volume":"130","author":"Corvaja","year":"2024","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.phymed.2025.156973_bib0008","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4103\/pr.pr_111_18","article-title":"Secondary metabolites from Lichen Usnea longissima and its pharmacological relevance","volume":"11","author":"Dandapat","year":"2019","journal-title":"Pharmacogn. Res."},{"key":"10.1016\/j.phymed.2025.156973_bib0009","doi-asserted-by":"crossref","first-page":"a031542","DOI":"10.1101\/cshperspect.a031542","article-title":"Genetically engineered mouse models of K-ras-driven lung and pancreatic tumors: validation of therapeutic targets","volume":"8","author":"Drosten","year":"2018","journal-title":"Cold. Spring. Harb. Perspect. Med."},{"key":"10.1016\/j.phymed.2025.156973_bib0010","article-title":"Optimizing Osimertinib for NSCLC: targeting resistance and exploring combination therapeutics","volume":"17","author":"Fabrizio","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.phymed.2025.156973_bib0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-022-01391-4","article-title":"Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance","volume":"15","author":"Fu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.phymed.2025.156973_bib0012","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70059","article-title":"Patient-derived xenograft model in cancer: establishment and applications","volume":"6","author":"Gu","year":"2025","journal-title":"MedComm"},{"key":"10.1016\/j.phymed.2025.156973_bib0013","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1158\/2159-8290.CD-22-0586","article-title":"Osimertinib + Savolitinib to overcome acquired MET-mediated resistance in epidermal growth factor receptor-mutated, MET-amplified non-small cell lung cancer: TATTON","volume":"13","author":"Hartmaier","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.phymed.2025.156973_bib0014","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.apsb.2015.07.001","article-title":"Mechanisms of resistance to EGFR tyrosine kinase inhibitors","volume":"5","author":"Huang","year":"2015","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.phymed.2025.156973_bib0015","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3390\/ijms25010616","article-title":"Attenuation of PI3K-akt-mTOR pathway to reduce cancer stemness on chemoresistant lung cancer cells by Shikonin and synergy with BEZ235 inhibitor","volume":"25","author":"Huang","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phymed.2025.156973_bib0016","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1200\/JCO.21.01719","article-title":"Practical management of oligometastatic non\u2013small-cell lung cancer","volume":"40","author":"Jasper","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phymed.2025.156973_bib0017","doi-asserted-by":"crossref","first-page":"7051056","DOI":"10.21037\/apm-20-1477","article-title":"Sequential use of EGFR-tyrosine kinase inhibitors based upon EGFR mutation evolution achieves long-term control in a non-small cell lung cancer patient: a case report","volume":"10","author":"Jiang","year":"2021","journal-title":"Ann. Palliat. Med."},{"key":"10.1016\/j.phymed.2025.156973_bib0018","doi-asserted-by":"crossref","first-page":"60","DOI":"10.2217\/lmt-2023-0003","article-title":"Survival and quality-of-life outcomes in early-stage NSCLC patients: a literature review of real-world evidence","volume":"12","author":"Jovanoski","year":"2023","journal-title":"Lung Cancer Manage"},{"key":"10.1016\/j.phymed.2025.156973_bib0019","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.drup.2015.05.002","article-title":"Fighting cancer drug resistance: opportunities and challenges for mutation-specific EGFR inhibitors","volume":"20","author":"Juchum","year":"2015","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.phymed.2025.156973_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.121093","article-title":"Inhibition of thioredoxin reductase 1 by vulpinic acid suppresses the proliferation and migration of human breast carcinoma","volume":"310","author":"Kal\u0131n","year":"2022","journal-title":"Life Sci."},{"key":"10.1016\/j.phymed.2025.156973_bib0021","doi-asserted-by":"crossref","first-page":"94","DOI":"10.17480\/psk.2024.68.2.94","article-title":"Synthesis of effective compounds and evaluation of anticancer activity for overcoming gefitinib resistance in non-small cell lung cancer","volume":"68","author":"Kim","year":"2024","journal-title":"Yakhak Hoeji"},{"key":"10.1016\/j.phymed.2025.156973_bib0022","article-title":"Euphorbiasteroid abrogates EGFR and wnt\/\u03b2-catenin signaling in non-small-cell lung cancer cells to impart anticancer activity","volume":"27","author":"Kim","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.phymed.2025.156973_bib0023","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01111-21","article-title":"Linking a gene cluster to atranorin, a major cortical substance of lichens, through genetic dereplication and heterologous expression","volume":"12","author":"Kim","year":"2021","journal-title":"mBio"},{"key":"10.1016\/j.phymed.2025.156973_bib0024","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1158\/1535-7163.MCT-16-0407","article-title":"Characterization of EGFR T790M, L792F, and C797S mutations as mechanisms of acquired resistance to afatinib in lung cancer","volume":"16","author":"Kobayashi","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phymed.2025.156973_bib0025","article-title":"Combination of osimertinib and pembrolizumab successfully overcome dual resistances in a patient with advanced adenocarcinoma of the lung, a case report","volume":"5","author":"Kulendran","year":"2022","journal-title":"Curr. Prob. Cancer Case Rep."},{"key":"10.1016\/j.phymed.2025.156973_bib0026","doi-asserted-by":"crossref","first-page":"152","DOI":"10.7150\/jca.77788","article-title":"Discovery of HCD3514 as a potent EGFR inhibitor against C797S mutation in vitro and in vivo","volume":"14","author":"Lai","year":"2023","journal-title":"J. Cancer"},{"key":"10.1016\/j.phymed.2025.156973_bib0027","article-title":"Drug resistance in late-stage epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer patients after first-line treatment with tyrosine kinase inhibitors","volume":"26","author":"Lee","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phymed.2025.156973_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2021.153831","article-title":"A method establishment and comparison of in vivo lung cancer model development platforms for evaluation of tumour metabolism and pharmaceutical efficacy","volume":"96","author":"Liang","year":"2022","journal-title":"Phytomedicine"},{"key":"10.1016\/j.phymed.2025.156973_bib0029","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1186\/s12885-024-13168-8","article-title":"EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis","volume":"24","author":"Liu","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.phymed.2025.156973_bib0030","article-title":"Patient-derived xenograft models: current status, challenges, and innovations in cancer research","author":"Liu","year":"2025","journal-title":"Genes Dis."},{"key":"10.1016\/j.phymed.2025.156973_bib0031","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1158\/1078-0432.CCR-17-1875","article-title":"Targeting HER2 aberrations in non-small cell lung cancer with Osimertinib","volume":"24","author":"Liu","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phymed.2025.156973_bib0032","first-page":"4","article-title":"Patient-derived xenograft models in cancer therapy: technologies and applications","volume":"8","author":"Liu","year":"2023","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.phymed.2025.156973_bib0033","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12123572","article-title":"Prognostic factors and long-term survival in locally advanced NSCLC with pathological complete response after surgical resection following neoadjuvant therapy","volume":"12","author":"Lococo","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.phymed.2025.156973_bib0034","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non\u2013small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.phymed.2025.156973_bib0035","first-page":"1","article-title":"In vitro, in vivo and in silico anticancer activity and toxicity of Usnic acid extracted from the mycobiont culture of Usnea baileyi","author":"Mariraj","year":"2024","journal-title":"Naunyn. Schmiedebergs. Arch. Pharmacol."},{"key":"10.1016\/j.phymed.2025.156973_bib0036","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3892\/ijo.2017.4036","article-title":"Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model","volume":"51","author":"Masuda","year":"2017","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.phymed.2025.156973_bib0037","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/1759-7714.14858","article-title":"Precision targeted therapy for EGFR mutation-positive NSCLC: dilemmas and coping strategies","volume":"14","author":"Meng","year":"2023","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.phymed.2025.156973_bib0038","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11864-018-0588-z","article-title":"Proton therapy in non-small cell lung cancer","volume":"19","author":"Mesko","year":"2018","journal-title":"Curr. Treat. Options. Oncol."},{"key":"10.1016\/j.phymed.2025.156973_bib0039","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.lungcan.2009.05.022","article-title":"Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status","volume":"68","author":"Onitsuka","year":"2010","journal-title":"Lung Cancer"},{"key":"10.1016\/j.phymed.2025.156973_bib0040","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41388-023-02929-7","article-title":"Genetically-engineered mouse models of small cell lung cancer: the next generation","volume":"43","author":"Oser","year":"2024","journal-title":"Oncogene"},{"key":"10.1016\/j.phymed.2025.156973_bib0041","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.gendis.2022.07.023","article-title":"Non-small cell lung carcinoma (NSCLC): implications on molecular pathology and advances in early diagnostics and therapeutics","volume":"10","author":"Padinharayil","year":"2023","journal-title":"Genes Dis."},{"key":"10.1016\/j.phymed.2025.156973_bib0042","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12935-022-02454-9","article-title":"Patient-derived xenograft models in hepatopancreatobiliary cancer","volume":"22","author":"Pan","year":"2022","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.phymed.2025.156973_bib0043","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/nrc2947","article-title":"Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer","volume":"10","author":"Pao","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phymed.2025.156973_bib0044","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1158\/1078-0432.CCR-22-3379","article-title":"IL6 Mediates suppression of T- and NK-cell function in EMT-associated TKI-resistant EGFR-mutant NSCLC","volume":"29","author":"Patel","year":"2023","journal-title":"Clinic. Cancer Res."},{"key":"10.1016\/j.phymed.2025.156973_bib0045","doi-asserted-by":"crossref","first-page":"6758","DOI":"10.1158\/0008-5472.CAN-13-2994","article-title":"EGFR activation and signaling in cancer cells are enhanced by the membrane-bound metalloprotease MT4-MMP","volume":"74","author":"Paye","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.phymed.2025.156973_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107249","article-title":"The significance of co-mutations in EGFR-mutated non-small cell lung cancer: optimizing the efficacy of targeted therapies?","volume":"181","author":"Pezzuto","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.phymed.2025.156973_bib0047","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.phymed.2025.156973_bib0048","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1200\/JCO.2010.30.8304","article-title":"How genetically engineered mouse tumor models provide insights into human cancers","volume":"29","author":"Politi","year":"2011","journal-title":"J. Clinic. Oncol."},{"key":"10.1016\/j.phymed.2025.156973_bib0049","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.7150\/jca.77619","article-title":"Clinical implications of the interaction between PD-1\/PD-L1 and PI3K\/AKT\/mTOR pathway in progression and treatment of non-small cell lung cancer","volume":"13","author":"Quan","year":"2022","journal-title":"J. Cancer"},{"key":"10.1016\/j.phymed.2025.156973_bib0050","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1111\/cas.13763","article-title":"Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer","volume":"109","author":"Sato","year":"2018","journal-title":"Cancer Sci."},{"key":"10.1016\/j.phymed.2025.156973_bib0051","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114643","article-title":"Fighting tertiary mutations in EGFR-driven lung-cancers: current advances and future perspectives in medicinal chemistry","volume":"190","author":"Scalvini","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.phymed.2025.156973_bib0052","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002003","article-title":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors","volume":"3","author":"Sequist","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.phymed.2025.156973_bib0053","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J. Clinical Oncol."},{"key":"10.1016\/j.phymed.2025.156973_bib0054","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1016\/j.cllc.2019.12.003","article-title":"Tyrosine kinase inhibitors for the treatment of EGFR mutation-positive non\u2013small-cell lung cancer: a clash of the generations","volume":"21","author":"Shah","year":"2020","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.phymed.2025.156973_bib0055","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.molmed.2015.04.001","article-title":"EGFR and NF-\u03baB: partners in cancer","volume":"21","author":"Shostak","year":"2015","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.phymed.2025.156973_bib0056","doi-asserted-by":"crossref","first-page":"190","DOI":"10.12688\/f1000research.17964.1","article-title":"Does the mouse tail vein injection method provide a good model of lung cancer?","volume":"8","author":"Shrestha","year":"2019","journal-title":"F1000Res."},{"key":"10.1016\/j.phymed.2025.156973_bib0057","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.phymed.2025.156973_bib0058","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1479-5876-8-135","article-title":"Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer","volume":"8","author":"Simonetti","year":"2010","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.phymed.2025.156973_bib0059","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR -mutated advanced non\u2013small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.phymed.2025.156973_bib0060","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.mam.2015.05.004","article-title":"Targeting EGFR in lung cancer: lessons learned and future perspectives","volume":"45","author":"Steuer","year":"2015","journal-title":"Mol. Asp. Med."},{"key":"10.1016\/j.phymed.2025.156973_bib0061","doi-asserted-by":"crossref","first-page":"5489","DOI":"10.1158\/1078-0432.CCR-10-1371","article-title":"Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer","volume":"16","author":"Suda","year":"2010","journal-title":"Clinic. Cancer Res."},{"key":"10.1016\/j.phymed.2025.156973_bib0062","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/2211-5463.13486","article-title":"A mouse model of lung cancer induced via intranasal injection for anticancer drug screening and evaluation of pathology","volume":"13","author":"Tanaka","year":"2022","journal-title":"FEBS Open Bio"},{"key":"10.1016\/j.phymed.2025.156973_bib0063","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40170-024-00365-z","article-title":"TDO2 inhibition counters Benzo[a]pyrene-induced immune evasion and suppresses tumorigenesis in lung adenocarcinoma","volume":"12","author":"Ta\u015f","year":"2024","journal-title":"Cancer Metab."},{"key":"10.1016\/j.phymed.2025.156973_bib0064","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-025-01119-9","article-title":"EGF receptor in organ development, tissue homeostasis and regeneration","volume":"32","author":"Tito","year":"2025","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.phymed.2025.156973_bib0065","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1021\/jacsau.3c00774","article-title":"Usnic acid targets 14-3-3 proteins and suppresses cancer progression by blocking substrate interaction","volume":"4","author":"Varl\u0131","year":"2024","journal-title":"JACS Au"},{"key":"10.1016\/j.phymed.2025.156973_bib0066","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e19185","article-title":"A fatty acid-rich fraction of an endolichenic fungus Phoma sp. suppresses immune checkpoint markers via AhR\/ARNT and ESR1","volume":"9","author":"Varl\u0131","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.phymed.2025.156973_bib0067","first-page":"159","article-title":"Tumor microenvironment in human tumor xenografted mouse models","volume":"3","author":"Varna","year":"2014","journal-title":"J. Anal. Oncol."},{"key":"10.1016\/j.phymed.2025.156973_bib0068","article-title":"Validation of an orthotopic non-small cell lung cancer mouse model, with left or right tumor growths, to use in conformal radiotherapy studies","volume":"18","author":"Wang","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.phymed.2025.156973_bib0069","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13045-016-0290-1","article-title":"EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer","volume":"9","author":"Wang","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.phymed.2025.156973_bib0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2024.156278","article-title":"Casticin inhibits proliferation of non-small cell lung cancer cells through regulating reprogramming of glucose metabolism","volume":"136","author":"Wei","year":"2025","journal-title":"Phytomedicine"},{"key":"10.1016\/j.phymed.2025.156973_bib0071","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109032","article-title":"Apoptosis induction and AKT\/NF-\u03bab inactivation are associated with regroafenib-inhibited tumor progression in non-small cell lung cancer in vitro and in vivo","volume":"116","author":"Weng","year":"2019","journal-title":"Biomed. Pharmacotherapy"},{"key":"10.1016\/j.phymed.2025.156973_bib0072","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","article-title":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial","volume":"18","author":"Wu","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.phymed.2025.156973_bib0073","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1200\/JCO.2018.77.7326","article-title":"Phase ib\/II study of Capmatinib (INC280) plus Gefitinib after failure of epidermal growth factor receptor (EGFR) inhibitor therapy in patients with EGFR-mutated, MET factor-dysregulated non-small-cell lung cancer","volume":"36","author":"Wu","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phymed.2025.156973_bib0074","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2045-3701-5-7","article-title":"Up-regulation of the Hippo pathway effector TAZ renders lung adenocarcinoma cells harboring EGFR-T790M mutation resistant to gefitinib","volume":"5","author":"Xu","year":"2015","journal-title":"Cell Biosci."},{"key":"10.1016\/j.phymed.2025.156973_bib0075","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1248\/cpb.43.1388","article-title":"Screening of tissue cultures and thalli of lichens and some of their active constituents for inhibition of tumor promoter-induced Epstein-Barr Virus activation","volume":"43","author":"Yamamoto","year":"1995","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"key":"10.1016\/j.phymed.2025.156973_bib0076","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1158\/1078-0432.CCR-21-4329","article-title":"Osimertinib plus Selumetinib in EGFR-mutated non-small cell lung cancer after progression on EGFR-TKIs: a phase ib, open-label, multicenter trial (TATTON Part B)","volume":"28","author":"Yang","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phymed.2025.156973_bib0077","doi-asserted-by":"crossref","first-page":"288","DOI":"10.21037\/tlcr.2016.06.07","article-title":"Non-small cell lung cancer: current treatment and future advances","volume":"5","author":"Zappa","year":"2016","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.phymed.2025.156973_bib0078","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1111\/1759-7714.12889","article-title":"Combined therapy with osimertinib and afatinib in a lung adenocarcinoma patient with EGFR T790M mutation and multiple HER2 alterations after resistance to icotinib: a case report","volume":"9","author":"Zhang","year":"2018","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.phymed.2025.156973_bib0079","article-title":"Ethacrynic acid enhances the antitumor effects of Afatinib in EGFR\/T790M-mutated NSCLC by inhibiting WNT\/beta-catenin pathway activation","volume":"2021","author":"Zhang","year":"2021","journal-title":"Dis. Markers"},{"key":"10.1016\/j.phymed.2025.156973_bib0080","doi-asserted-by":"crossref","first-page":"6828","DOI":"10.1021\/acsomega.3c08136","article-title":"The depside derivative pericodepside inhibits cancer cell metastasis and proliferation by suppressing epithelial-mesenchymal transition","volume":"9","author":"Zhou","year":"2024","journal-title":"ACS Omega"},{"key":"10.1016\/j.phymed.2025.156973_bib0081","first-page":"1","article-title":"The lichen secondary metabolite atranorin suppresses lung cancer cell motility and tumorigenesis","volume":"7","author":"Zhou","year":"2017","journal-title":"Sci. Rep."}],"container-title":["Phytomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0944711325006117?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0944711325006117?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,10]],"date-time":"2025-08-10T06:32:22Z","timestamp":1754807542000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0944711325006117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":81,"alternative-id":["S0944711325006117"],"URL":"https:\/\/doi.org\/10.1016\/j.phymed.2025.156973","relation":{},"ISSN":["0944-7113"],"issn-type":[{"value":"0944-7113","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"4-O-Demethylbarbatic acid has a novel therapeutic impact on the progression of EGFR-driven lung adenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Phytomedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phymed.2025.156973","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier GmbH. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156973"}}